Department of Neuroscience and Rehabilitation, University of Ferrara, I-44121 Ferrara, Italy.
Department of Medical, Oral and Biotechnological Sciences, Center for Advanced Studies and Technology ‑ CAST, University G. d'Annunzio of Chieti‑Pescara, 66100 Chieti, Italy.
Int J Mol Med. 2021 Apr;47(4). doi: 10.3892/ijmm.2021.4890. Epub 2021 Feb 19.
Glucosamine (GlcN) functions as a building block of the cartilage matrix, and its multifaceted roles in promoting joint health have been extensively investigated. However, the role of GlcN in osteogenesis and bone tissue is poorly understood, mainly due to the lack of adequate experimental models. As a result, the benefit of GlcN application in bone disorders remains controversial. In order to further elucidate the pharmacological relevance and potential therapeutic/nutraceutic efficacy of GlcN, the effect of GlcN treatment was investigated in human primary osteoclasts (hOCs) and osteoblasts (hOBs) that were cultured with two‑dimensional (2D) traditional methods or co‑cultured in a 3D dynamic system more closely resembling the bone microenvironment. Under these conditions, osteoclastogenesis was supported by hOBs and sizeable self‑assembling aggregates were obtained. The differentiated hOCs were evaluated using tartrate‑resistant acid phosphatase assays and osteogenic differentiation was monitored by analyzing mineral matrix deposition via Alizarin Red staining, with expression of specific osteogenic markers determined via reverse transcription‑quantitative PCR. It was found that crystalline GlcN sulfate was effective in decreasing osteoclastic cell differentiation and function. hOCs isolated from patients with OA were more sensitive compared with those from healthy donors. Additionally, GlcN exhibited anabolic effects on hOCs both in 2D conventional cell culture and in hOC/hOB 3D dynamic co‑culture. The present study demonstrated for the first time the effectiveness of a 3D dynamic co‑culture system for characterizing the spectrum of action of GlcN on the bone microenvironment, which may pave the way for more fully determining the potential applications of a compound such as GlcN, which is positioned between pharmaceuticals and nutraceuticals. Based on the present findings, it is hypothesized that GlcN may have potential benefits in the treatment of osteopenic diseases such as osteoporosis, as well as in bone maintenance.
氨基葡萄糖(GlcN)是软骨基质的组成部分,其在促进关节健康方面的多效作用已得到广泛研究。然而,GlcN 对成骨和骨组织的作用知之甚少,主要是因为缺乏足够的实验模型。因此,GlcN 在骨骼疾病中的应用效果仍存在争议。为了进一步阐明 GlcN 的药理学相关性及其在治疗和营养方面的潜在疗效,本研究采用二维(2D)传统培养方法或在更接近骨微环境的 3D 动态系统中进行共培养的方法,研究了 GlcN 处理对原代人破骨细胞(hOCs)和人成骨细胞(hOBs)的影响。在这些条件下,hOBs 支持破骨细胞的分化,并获得了大量自组装的聚集物。通过抗酒石酸酸性磷酸酶检测评估分化的 hOCs,通过茜素红染色分析矿化基质沉积来监测成骨分化,并通过逆转录定量 PCR 确定特定成骨标志物的表达。结果发现,结晶 GlcN 硫酸盐可有效抑制破骨细胞的分化和功能。与健康供体相比,来自骨关节炎(OA)患者的 hOCs 更为敏感。此外,GlcN 在 2D 常规细胞培养和 hOC/hOB 3D 动态共培养中对 hOCs 均具有合成代谢作用。本研究首次证明 3D 动态共培养系统可有效用于研究 GlcN 对骨微环境作用谱,这可能为更全面地确定 GlcN 等化合物的潜在应用铺平道路,GlcN 介于药物和营养保健品之间。基于本研究结果,假设 GlcN 可能在骨质疏松等骨疏松性疾病的治疗以及骨维持方面具有潜在益处。